SCDF StaffMar 14 minFDA Approves First Gene Therapies to Treat Patients with Sickle Cell DiseaseDecember 8, 2023. Today the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the...
SCDF StaffFeb 212 minFDA Approves Novartis' Adakveo for Pain Events Associated with Sickle Cell DiseaseThe U.S.Food and Drug Administration (FDA)approvedNovartis’ Adakveo (crizanlizumab) to decrease the frequency of vaso-occlusive crises...
SCDF StaffFeb 213 minFDA Approves Oxbryta™, First Medicine Specifically Targeting the Root Cause of Sickle Cell DiseaseOxbryta (voxelotor), a first sickle cell treatment that works to stop the sickling and destruction of red blood cells that mark this...
SCDF StaffFeb 213 minNCSCC: Uplifting Sickle Cell Disease as a statewide priorityThe Networking California for Sickle Cell Care Initiative (NCSCC) was developed through advocacy and stakeholder engagement supported by...